Neoplasma Vol.70, No.6, p. 811–818, 2023
|
| Title: Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial |
| Author: Dongming Liu, Han Mu, Changfu Liu, Weihao Zhang, Yunlong Cui, Qiang Wu, Xiaolin Zhu, Feng Fang, Wei Zhang, Wenge Xing, Qiang Li, Tianqiang Song, Wei Lu, Huikai Li |
|
Abstract: We assessed the efficacy and safety of sintilimab [an anti-programmed death (PD-1)] plus bevacizumab biosimilar (IBI305), and hepatic arterial infusion chemotherapy (HAIC) in patients with unresectable hepatocellular carcinoma (HCC). The patients received sintilimab (200 mg) plus IBI305 (7.5 mg/kg) and HAIC (FOLFOX for 23 h) and were treated every 3 weeks. The primary endpoint was the objective response rate (ORR) assessed by an independent review committee (IRC) per mRECIST v1.1. Twenty-nine patients were enrolled in our clinical trial (1 patient voluntarily withdrew due to adverse events after the initial treatment). Objective response was reached in 17/29 (58.6%) patients per mRECIST. A total of 19/29 (65.5%) patients became eligible for further treatment; 14 of them completed surgical resection; 1 (5.3%) achieved pathological complete response (pCR); and 5 (26.3%) reached major partial response (mPR). The 1-year OS rate was better in the PR or pCR+mPR+PR group than in the PD+SD group by either mRECIST or pathological assessment (p=0.039 and 0.006). The 1-year EFS rate was better in the PR group than in the PD+SD group by pathological assessment (p=0.007). The most common treatment-related adverse events (TEAEs) in 30 HCC patients included thrombocytopenia (40.0%), hypertension (23.3%), and leukopenia (23.3%). The grade 3-5 TEAEs that were observed were hypertension (10%), diarrhea (6.7%), asthenia (3.3%), and ascites (3.3%). Sintilimab plus IBI305 and HAIC showed promising efficacy and manageable safety in patients with unresectable HCC. It might represent a novel treatment option for these patients.
|
|
| Keywords: sintilimab, bevacizumab biosimilar, hepatic arterial infusion chemotherapy, efficacy, safety |
|
|
Published online: 19-Jan-2024
|
| Year: 2023, Volume: 70, Issue: 6 |
Page From: 811, Page To: 818 |
doi:10.4149/neo_2023_230806N413
|
|
 download file |
|
|
|
|
